EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported
By Ludwig Burger and Maggie Fick (Reuters) -The European Medicines Agency (EMA) is investigating Novo Nordisk’s diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland’s health regulator flagged three cases of patients thinking about suicide or self-harm. Shares of the Danish drugmaker fell 1% on Monday following the news. An EMA safety committee is looking…
